| Basics |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
|
| IPO Date: |
July 24, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.27B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.22 | 2.55%
|
| Avg Daily Range (30 D): |
$0.71 | 2.01%
|
| Avg Daily Range (90 D): |
$0.70 | 2.28%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
.47M |
| Avg Daily Volume (90 D): |
.47M |
| Trade Size |
| Avg Trade Size (Sh.): |
75 |
| Avg Trade Size (Sh.) (30 D): |
48 |
| Avg Trade Size (Sh.) (90 D): |
48 |
| Institutional Trades |
| Total Inst.Trades: |
5,699 |
| Avg Inst. Trade: |
$2.35M |
| Avg Inst. Trade (30 D): |
$2.72M |
| Avg Inst. Trade (90 D): |
$2.65M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.18M |
| Avg Closing Trade (30 D): |
$4.1M |
| Avg Closing Trade (90 D): |
$3.66M |
| Avg Closing Volume: |
76.86K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$11.69
|
$-1.55
|
$-1.72
|
|
Diluted EPS
|
$11.24
|
$-1.55
|
$-1.74
|
|
Revenue
|
$ 37.04M
|
$ 8.73M
|
$ 10.73M
|
|
Gross Profit
|
$ 32.41M
|
$ 7.64M
|
$ 9.47M
|
|
Net Income / Loss
|
$ 665.99M
|
$ -89.29M
|
$ -96.52M
|
|
Operating Income / Loss
|
$ -440.29M
|
$ -106.63M
|
$ -125.04M
|
|
Cost of Revenue
|
$ 4.62M
|
$ 1.09M
|
$ 1.26M
|
|
Net Cash Flow
|
$ -39.8M
|
$ 2.72M
|
$ -177.48M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
